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Mitotic catastropheCancer cells with defective DNA decatenation checkpoint can be selectively targeted by the catalytic inhibitors of
DNA topoisomerase IIα (topo IIα) enzyme. Upon treatmentwith catalytic topo IIα inhibitors, cellswith defective
decatenation checkpoint fail to arrest their cell cycle in G2 phase and enter into M phase with catenated and
under-condensed chromosomes resulting into impaired mitosis and eventually cell death. In the present work
we analyzed decatenation checkpoint in ﬁve different colon cancer cell lines (HCT116, HT-29, Caco2, COLO 205
and SW480) and in one non-cancerous cell line (HEK293T). Four out of the ﬁve colon cancer cell lines i.e.
HCT116, HT-29, Caco2, and COLO 205 were found to be compromised for the decatenation checkpoint function
at different extents,whereas SW480 andHEK293T cell lineswere found to be proﬁcient for the checkpoint function.
Upon treatment with ICRF193, decatenation checkpoint defective cell lines failed to arrest the cell cycle in G2 phase
and entered intoM phase without proper chromosomal decatenation, resulting into the formation of tangledmass
of catenated and under-condensed chromosomes. Such cells underwent mitotic catastrophe and rapid apoptosis
like cell death and showed higher sensitivity for ICRF193. Our study suggests that catalytic inhibitors of topoisom-
erase IIα are promising therapeutic agents for the treatment of colon cancers with defective DNA decatenation
checkpoint.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
As a consequence of the genome replication in S phase, DNA catena-
tions are formedbetween sister chromatids [1]. These catenationsphys-
ically link sister DNAs and thus must be resolved to allow proper
chromosome condensation and segregation in prophase and anaphase,
respectively. In G2 phase of the cell cycle these catenations are resolved by
the action of a highly conserved eukaryotic enzyme topoisomerase IIα
(topo IIα). Chromatid catenations are actively monitored in human cells
by a G2 phase decatenation checkpoint which delays entry to mitosis
until all the catenations in the genome have been removed. However
Bower et al. [2], have shown that the checkpoint does not sense cat-
enations but rather it senses the catalytically inactive form of topo
IIα tethered to DNA. Although complete signaling pathway for theia telangiectasiamutated; Chk2,
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(H.K. Majumder).decatenation checkpoint is not well understood, this checkpoint has
been widely studied during last decade in different types of cancers
including lung cancer, leukemia, bladder cancer and melanoma [3–6].
Failure to properly resolve sister chromatids has been proposed to lead
nondisjunction, loss of heterozygosity, aneuploidy and translocation,
which are causes of genomic instability [5,7–9].
Topoisomerase inhibitors are widely used in anticancer chemother-
apy. Topoisomerase inhibitors are classiﬁed into two different catego-
ries: class I topoisomerase inhibitors or topoisomerase poisons inhibit
strand rotation or re-ligation step of the enzymatic reaction and thereby
stabilize topoisomerase-DNA covalent complexes, whereas class II
topoisomerase inhibitors or catalytic topoisomerase inhibitors inhibit
either DNA binding or DNA cleavage step of the enzymatic reaction
and thereby do not generate DNA breaks. Etoposide is a class I inhibitor
of topo IIα. It stabilizes covalent topo II-DNA complexes and thereby
forms double strand DNA breaks. ICRF193, a bisdioxopiperazine, is a
class II or catalytic inhibitor of topo IIα. ICRF193 inhibits ATPase activity
of the enzyme and stabilizes the enzyme in closed clamp position there-
by the enzyme cannot decatenate sister chromatid DNA and induce
decatenation checkpoint pathway which arrests cells in G2 phase [10,
11]. Studies have shown that ATM (ataxia telangiectasiamutated) kinase
and Rad9A are required for the activation of decatenation checkpoint
and upon treatment with ICRF193, ATM is autophosphorylated at
serine-1981 [12,13]. PhosphorylatedATMsubsequently phosphorylates
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Phosphorylated Chk2 phosphorylates Cdc25C which prevents mitotic
entry [15]. Luo et al. [16], have shown that during the activation of
decatenation checkpoint topo IIα is phosphorylated at Ser-1524, facili-
tating interaction of topo IIα with MDC1 (mediator of DNA damage
checkpoint protein-1).
Adjuvant 5-ﬂuorouracil (5-FU) based chemotherapy in patients
with resected stage III colorectal cancer improves recovery of the
disease and overall survival rate by 35% and 22%, respectively [17]. But
in advance stage CRC response rates for 5-FU based monotherapy is
only 10–15% [18]. Combinations of 5-FU with CPT-11 and oxaliplatin
improves response rates to 40–50% and prolonged progression-free
survival [19,20]. Although these improvements have been made but
more than half of the patients with advanced stage colorectal cancer do
not show any measurable shrinkage in their tumors [21], thus improve-
ment in the current chemotherapy for colorectal cancer and identiﬁcation
of novel chemotherapeutic targets for colorectal cancer are justiﬁed.
In this study we analyzed G2 phase decatenation checkpoint in ﬁve
different colon cancer cell lines (HCT116, HT-20, Caco2, COLO 205 and
SW480) and in one non-cancerous cell line (HEK293T). Four out of the
ﬁve cell lines i.e. HCT116, HT-20, Caco2 and COLO 205 were found to be
defective for the checkpoint function at different extents while SW480
and HEK293T cell lines efﬁciently blocked their cell cycle in G2 phase
after ICRF193 treatment. We found that such decatenation checkpoint
defective cells undergo mitotic catastrophe and rapid cell death and
show higher sensitivity for catalytic topo II inhibitor, ICRF193. Mitotic ca-
tastrophe describes a form of cell death affectingmammalian cells during
mitosis. Mitotic catastrophe is characterized by the formation of large
cells containing large and multiple nuclei (fragmented nuclei). Such
cells are morphologically distinguishable from apoptotic cells [22].2. Materials and methods
2.1. Cell culture and cell viability assay
All the cell lines were cultured in the ATCC recommended culture
media supplemented with 10% fetal bovine serum (GIBCO, Invitrogen,
Carlsbad, CA, US), 1× PSN (GIBCO) and gentamicin (GIBCO). Cells were
incubated in a humidiﬁed CO2 incubator at 37 °C. ICRF193 and etoposide
were purchased from Sigma (St. Louis, MO, US). For cell viability assay,
cells were seeded in 96 well plates and were treated with vehicle or
ICRF193 or etoposide for 48 h. After 48 h cells were treated with MTT
and formation of formazan was quantiﬁed on Thermo MULTISKAN EX
plate reader at 595 nm.2.2. Colony formation assay
Approximately 103 cells were seeded in 6 cm culture dishes and
treatedwith vehicle or ICRF193 or etoposide for 24 h. After the treatment
cellswere allowed to formcolonies for 15–20 days. Colonieswere stained
with 0.2% methylene blue. Colonies were counted in each plate and per-
centage of colonies formed was calculated.2.3. Cell synchronization
One day prior to start of synchronization, cells were seeded on
coverslips in 35 mm dishes. Next day 2.5 mM thymidine (Calbiochem,
San Diego, CA, US) was added to the dishes (ﬁrst thymidine block).
After 16 h of thymidine treatment cells were replenished with fresh
media. After 8 h again 2.5mM thymidinewas added to the cells (second
thymidine block). After 22 h cells were replenishedwith freshmedia. To
obtain G2 phase synchronized cells, cells were harvested/collected after
6 h of thymidine release.2.4. Measurement of mitotic indices
Immunostaining for phospho-histone H3 (serine-10) was per-
formed to identify the cells undergoing mitosis. G2 phase synchronized
cells were treated with vehicle or ICRF193 or etoposide at IC50 concen-
trations and were ﬁxed with acetone–methanol mixture (1:1) at 0, 2,
4 and 6 h post-treatment. Cells were washed with 1× PBS thrice and
permeabilized with 0.03% saponin for 30 min. Cells were washed with
1× PBS thrice and blocked in 3% BSA for 2 h on rocker. One hundred
microliters of p-histone H3 (serine-10) antibody (Santa Cruz Biotech-
nology, Inc. Santa Cruz, CA, USA) (1:50 dilution) was directly added
on to the cells and incubated overnight at 4 °C. Cells were washed
with 1× PBS thrice. One hundred microliters of FITC-tagged secondary
antibody (1:100 dilution) was directly added on to the cells and incu-
bated at room temperature for 2 h in the dark. Cells were mounted on
glass slides with 4′-6-diamidino-2-phenylindole (DAPI) and sealed
with nail enamel. Approximately 200 cells per slide were observed for
phosphorylation of histone H3 and percentage of mitotic cells (mitotic
index) was calculated.
2.5. Flow cytometry analysis of cell cycle and apoptosis
For cell cycle analysis, cellswereﬁxed in 70%ethanol for overnight at
4 °C. Next day cells were stained with propidium iodide/RNase staining
buffer (BD Biosciences, San Diego, CA, USA) and ﬂow cytometry
was performed. For detection of apoptosis, cells were stained with
FITC-annexin V and propidium iodide solution using apoptosis detec-
tion kit (BD Biosciences).
2.6. Immunoblotting
Cells were lysed in NP-40 lysis buffer and total cellular proteinswere
measured by Bradford's assay. Equal amounts of proteins were elec-
trophoresed on SDS-poly acryl amide gel, separated proteins were
transferred on to nitrocellulose membrane and immunoblotting was
performed using antibodies speciﬁc to the desired proteins.
2.7. Quantiﬁcation of G2 decatenation checkpoint function in colon cancer
cell lines
Synchronized cells were treated with vehicle or ICRF193 or etoposide
in G2 phase (6 h post-thymidine release). Cells were ﬁxed after 6 h of the
treatment (12hpost-thymidine release) and immunostainedusing cyclin
A2 antibody and FITC-tagged secondary antibody. Approximately 200
cells per slide were observed for cyclin A2 expression and extent of G2
checkpoint function was quantiﬁed by the following equation:
Percentage of G2 checkpoint functional cells = percentage of cyclin
A2 positive cells in ICRF193 or etoposide treated condition− percentage
of cyclin A2 positive cells in vehicle treated condition.
2.8. Nuclear extracts preparation and topoisomerase enzyme activity assay
Synchronized HCT116 and HEK293T cells were treated with vehicle
or 4 μM ICRF193 or 4 μM etoposide in G2 phase for 2 h and were
suspended in cytoplasmic extraction buffer containing 10 mM Tris–HCl
(pH 7.9), 340 mM sucrose, 3 mM CaCl2, 2 mM MgCl2, 100 μM EDTA,
1 mM DTT, 0.1% Nonidet P-40 and 1× protease inhibitor cocktail. Cells
were mixed with the buffer and centrifuged at 4000 rpm for 15 min at
4 °C. Supernatant was discarded and pellet was dissolved in nuclear
lysis buffer containing 20mMHEPES (pH 7.9), 3 mM EDTA, 10% glycerol,
150mMpotassium acetate, 1.5mMMgCl2, 1mMDTT, 0.1%Nonidet P-40
and 1×protease inhibitor cocktail. Suspensionwas cleared by centrifuga-
tion at 13,000 rpm for 10 min at 4 °C. Supernatant (nuclear extract) was
collected in fresh pre-chilled tubes and stored at−80 °C. DNA relaxation
assay for topoisomerases was performed using 50 μg of nuclear extract
per reaction. Brieﬂy 100 fmol of supercoiled pBlueScript (SK+) (pBS)
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containing 25 mM Tris–HCl (pH 7.5), 5% glycerol, 0.5 mM DTT, 10 mM
MgCl2, 50 mM KCl, 25 mM EDTA and 150 μg/ml BSA. Reaction mixtures
were incubated at 37 °C for 30 min and electrophoresed in 1% agarose
gel at 1.0 V/cm for 10–12 h. Gels were stained with 0.5 μg/ml ethidium
bromide (EtBr) and viewed under UV illumination.
2.9. Chromosome preparation and Giemsa staining
G2 phase synchronized cells were treated with vehicle or 4 μM
ICRF193 for 2 h. Cells were re-suspended in 10 ml pre-warmed 0.56%
KCl (hypotonic solution) and kept at 37 °C for 12 min. About 3–4
drops of ﬁxative (acetic acid andmethanol, 1:3) were added to the sus-
pension and centrifuged at 1500 rpm for 5 min. The hypotonic solution
was completely discarded. Ten milliliters of fresh ﬁxative was added to
the pellet and incubated at room temperature for 15min to ﬁx the cells.
This stepwas repeated 3 timeswith fresh ﬁxative and the resulting pellet
was dissolved in appropriate amount of fresh ﬁxative. For Giemsa
staining clean glass slides were wiped with methanol and 2–3 drops
of cell suspension were added on to glass slides from 20 cm height.
Slides were dried at 37 °C for 2 h and Giemsa stained for 5–6min. Slides
were washedwith distilled water twice andmounted in DPXmounting
reagent with cover glass. Chromosomes were visualized under bright
ﬁeld microscope using 100× oil immersion objective lens.
2.10. Assessment of mitotic catastrophe
HCT116 cells were treated with vehicle or 1 or 2 or 3 μM ICRF193 for
48 and 72 h. Cells were ﬁxed using methanol and acetic acid mixture
(1:1) and permeabilized using 0.01% saponin. Nuclei of ﬁxed cellsFig. 1.MTT cell viability assay. (A–F) Plots for MTT cell viability assay. The six cell lines were tre
assessed by MTT assay. Each error bar represents mean ± SDM for the three independent exp
mean± SDM for the three independent experiments with three technical repeats in each indepwere stained with DAPI and mitotic catastrophe was assessed in
approximately 100 nuclei per slide.3. Results
3.1. Majority of colon cancer cell lines show higher sensitivity for ICRF193
Effects of ICRF193 and etoposide on viability of the ﬁve colon cancer
cell lines (HCT116, HT-29, Caco2, COLO 205 and SW480) and one non-
cancerous cell line (HEK293T) were assessed by MTT assay (Fig. 1A–F).
In ICRF193 treated condition IC50 values for HCT116, HT-29, Caco2,
COLO 205, SW480 and HEK293T cell lines were found to be 1.29 ±
0.04 μM, 1.92 ± 0.05 μM, 2.42 ± 0.12 μM, 1.24 ± 0.05 μM, 3.29 ±
0.06 μM and 4.24 ± 0.19 μM, respectively (Fig. 1G). While in etoposide
treated condition IC50 values for HCT116, HT-29, Caco2, COLO 205,
SW480 and HEK293T cell lines were found to be 1.73 ± 0.21 μM,
7.2 ± 1.04 μM, 7.26 ± 1.68 μM, 1.61 ± 0.02 μM, 4.92 ± 0.33 μM
and 2.42 ± 0.05 μM, respectively. For ICRF193; HCT116, HT-29,
Caco2 and COLO 205 cell lines showed higher sensitivity than
SW480 and HEK293 cell lines. While for etoposide; HCT116, COLO
205 and HEK293T cell lines were found to be more sensitive than
HT-29, Caco2 and SW480 cell lines. In addition to MTT assay, colony
formation assay was also performed to assess sensitivity of the six
cell lines for ICRF193 and etoposide (Fig. 2A–F). Colony formation
assay corroborated the results of MTT assay. For ICRF193; HCT116,
HT-29, Caco2 and COLO 205 cell lines showed approximately three
fold higher sensitivities than SW480 cell line and approximately
four fold higher sensitivities than HEK293T cell line (Fig. 2G).
While for etoposide; HCT116, COLO 205 and HEK293T cell lines
were found to be more sensitive than HT-29, Caco2 and SW480 cellated with ICRF193 or etoposide at indicated concentrations for 48 h and cell viability was
eriments. (G) IC50 values of ICRF193 and etoposide for the six cell lines. Each IC50 value is
endent experiment. *P b 0.05, t-test (vehicle versus ICRF193 or vehicle versus etoposide).
Fig. 2. Colony formation assay. (A–F) Plots for colony formation assay. The six cell lines were treatedwith ICRF193 and etoposide at indicated concentrations for 24 h and were allowed to
form colonies for 15–20 days. Colonies were stained with 0.2% methylene blue and percentages of colonies formed were counted. Each error bar represents mean ± SDM for the three
independent experiments. (G) Concentrations of ICRF193 and etoposide where 50% inhibition of colony formation was achieved for the six cell lines. The concentrations are mean ± SDM
for the three independent experiments. *P b 0.05, t-test (vehicle versus ICRF193 or vehicle versus etoposide).
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show higher sensitivity for ICRF193.
3.2. G2 decatenation checkpoint function is compromised in the ICRF193
sensitive colon cancer cell lines
Cell viability assays and colony formation assays suggested that four
out of the ﬁve colon cancer cell lines show higher sensitivity for
ICRF193. Previous studies have shown that cell lines with defective G2
decatenation checkpoint pathway show higher sensitivity for the cata-
lytic topo II inhibitors [3]. Therefore we suspected that the ICRF193 sen-
sitive colon cancer cell lines might be defective for the decatenation
checkpoint function. To assess the decatenation checkpoint function in
the six cell lines, mitotic indices were measured. In mammalian cells
histone H3 is phosphorylated at serine-10 during mitosis. Histone H3
phosphorylation starts in prophase and reaches to peak level in
metaphase, while dephosphorylation of histone H3 starts in anaphase
and in telophase it is completely dephosphorylated [23]. HEK293T cell
line was used as control cell line as it does not express metnase and has
functional decatenation checkpoint [24].Metnase enhances Topo IIαme-
diated decatenation and thereby inhibits activation of the decatenation
checkpoint pathway [24]. To measure mitotic indices, G2 phase synchro-
nized cells were treated with vehicle or ICRF193 or etoposide at IC50
concentrations and phosphorylation of histone H3 was measured at 0,
2, 4 and 6 h post-treatment. Upon ICRF193 treatment mitotic indices of
HCT116, HT-29, Caco2 and COLO 205 cell lines gradually increased at 2,
4 and 6 h suggesting that the cells are not arrested in G2 phase but
enter into M phase and accumulate at metaphase stage (Fig. 3A–D).
While in vehicle treated conditionsmitotic indices reached to peak levels
at 4 h and declined at 6 h. Contrary to these results, SW480 andHEK293T
cell lines upon treatment with ICRF193 remained arrested in G2 phaseand did not enter into M phase as the mitotic indices were not increased
at 2, 4 and 6 h (Fig. 3E and F). These results suggest that the ICRF193
sensitive colon cancer cell lines, HCT116, HT-29, Caco2 and COLO 205
have compromised/impaired decatenation checkpoint function, while
SW480 and HEK293T cell lines have functional decatenation checkpoint
pathway. On the other hand, upon etoposide treatment all the six cell
lines remained arrested in the G2 phase and did not enter into M phase
as the mitotic indices were not increased at 2, 4 and 6 h, suggesting
that these cell lines efﬁciently block cell cycle progression in G2 phase
by activating G2 phase DNA damage checkpoint (Fig. 3A–F).
Cell cycle arrest in synchronizedHCT116 cellswas further analyzed by
ﬂow cytometry analysis. G2 phase synchronized HCT116 cells (i.e. 6 h
post-thymidine release) were treated with vehicle or ICRF193 at the
IC50 concentration or at 10 times above the IC50 concentration to study
more accurate comparison of the effect of ICRF193 on cell cycle arrest.
Cells were ﬁxed at 6, 8, 10, 12 and 14 h post-thymidine release and
ﬂow cytometry was performed. ICRF193 treated cells were found to be
arrested in G2/M phase at 10, 12 and 14 h whereas the vehicle treated
cells gradually crossed G2/M phase from 8 to 14 h (Fig. 4A and B,
Table 1, Supplementary Figs. 1 and 2). Cell cycle arrest was also analyzed
in asynchronously growing HCT116 cells. Cells were treated with vehicle
or ICRF193 at the IC50 concentration or at 10 times above the IC50 concen-
tration for 12, 24, 36 and 48 h and ﬂow cytometrywas performed (Fig. 4C
and D, Table 2, Supplementary Figs. 3 and 4). ICRF193 treated cells were
found to be arrested in G2/M phase in a time dependent manner and the
percentage of G2/M population increased from 12 to 48 h. Similar results
were observedwith the synchronizedHEK293T cells treatedwith vehicle
or ICRF193 at the IC50 concentration or at 10 times above the IC50 concen-
tration (Supplementary Fig. 5A–D).
G2/M arrest in response to ICRF193 and etoposide treatments was
further analyzed by determining cyclin A2 and cyclin B1 level. G2
Fig. 3.Mitotic indices for the six cell lines. (A–F) G2 phase synchronized cells were treatedwith vehicle or ICRF193 or etoposide at the IC50 concentrations and ﬁxed at 0, 2, 4 and 6 h post-
treatment. Cellswere immunostained for phospho-histoneH3 (ser-10) andmitotic indiceswere determined by calculating the percentage of phospho-histoneH3 positive cells. Each error
bar represents mean ± SDM for the three independent experiments. *P b 0.05, t-test (vehicle 4 h versus vehicle 0 h). #P b 0.05, t-test (ICRF193 6 h versus vehicle 6 h).
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vehicle or ICRF193 or etoposide at IC50 concentrations and harvested
at every one hour interval from 6 to 12 h post-thymidine release.
Immunoblottingwas performed for cyclin A2, cyclin B1 andβ-actin pro-
teins. In vehicle treated HCT116 cells, cyclin A2 degradation started at
9 h and its level completely abolished at 11 h whereas cyclin B1 expres-
sion peaked from 10 to 11 h and its level completely abolished at 12 h
(Fig. 4E and Supplementary Fig. 6A–C). Upon ICRF193 treatment cyclin
A2 was completely degraded at 10 h and cyclin B1 expression persisted
from 8 to 12 h, indicating that the cells are not arrested in G2 phase and
enter M phase. Contrary to these, upon etoposide treatment, cyclin A2
expression persisted till 12 h and cyclin B1 expression was not signiﬁ-
cant, indicating that the cells activate DNA damage checkpoint which
arrest cell cycle in G2 phase [25]. In vehicle treated HEK293T cells, cyclin
A2 degraded at 10 h and cyclin B1 expression peaked from 8 to 11 h
(Fig. 4E and Supplementary Fig. 6D). Upon ICRF193 and etoposide
treatments, cyclin A2 expressions persisted till 12 h while cyclin B1 ex-
pressions were not signiﬁcant, indicating G2 phase arrest (Fig. 4E and
Supplementary Fig. 6E and F). Cyclin A2 and cyclin B1 levelswere also an-
alyzed in the asynchronously growing HCT116 cells treated with vehicle
or ICRF193 at the IC50 concentration for 12, 24, 36 and48h. Upon ICRF193
treatment cyclin A2 levels were decreased after 36 and 48 h whereas cy-
clin B1 levels increased in the time dependent manner from 12 to 48 h,
suggesting accumulation of the cells in mitotic phase (Supplementary
Fig. 6G). According to Chang et al. [26], cyclin B1 degradation starts in
early metaphase and its level completely vanishes before the onset of
anaphase. Considering the results of mitotic indices and cyclin levels it
is apparent that upon ICRF193 treatment decatenation checkpoint defec-
tive HCT116 cells are accumulated at early metaphase stage as cyclin B1
levels are stabilized and histone H3 remains phosphorylated in the
cells. Together these results suggest that the ICRF193 sensitive
colon cancer cell lines have defects in the G2 decatenation check-
point function and upon treatment with ICRF193 they do not arrest
cell cycle in G2 phase but enter into M phase and accumulate at
early metaphase stage.3.3. Decatenation checkpoint function is compromised at different extents
among different colon cancer cell lines
Extent of the G2 decatenation/damage checkpoint function in the six
cell lines was calculated as described in the Materials and methods
section. Table 3 describes extents of the G2 decatenation/damage check-
point function in the six cell lines. For HCT1116 cell line, only 4.52 ±
3.38% cellswere found to be efﬁcient for theG2 decatenation checkpoint
function, suggesting that the cell line is severely compromised for
the checkpoint function. For HT-29, Caco2 and COLO 205 cell lines,
10.77 ± 4.45, 13.41 ± 5.61 and 29.02 ± 5.37% cells were found to be
efﬁcient for the G2 decatenation checkpoint function, respectively. Con-
trary to these results, for SW480 and HEK293T cell lines, 79.35 ± 2.55
and 81.4 ± 3.5% cells were found to be efﬁcient for the G2 decatenation
checkpoint function, respectively. Whereas the G2 DNA damage check-
point function was quite high in all the cell lines. For HCT116, HT-29,
Caco2, COLO 205, SW480 and HEK293T cell lines; 70.18 ± 16.14,
67.6 ± 8.25, 48.96 ± 10.62, 59.67 ± 17.35, 63.74 ± 8.83 and 66.86 ±
4.27% cells were found to be G2 DNA damage checkpoint functional,
respectively. These results corroborate the results of mitotic indices
and suggest that the extent of G2 decatenation checkpoint function
varies among the ﬁve colon cancer cell lines.3.4. Decatenation checkpoint pathway is not activated inHCT116 cells upon
inhibition of DNA decatenation
To check activation of the decatenation checkpoint pathway we
examined the phosphorylations of ATM at serine-1981 and Chk2 at
threonine-68. G2 phase synchronized HCT116 and HEK293T cells were
treated with vehicle or ICRF193 or etoposide at IC50 concentrations.
Cells were harvested after 2 h of the treatment and immunoblotting
was performed. In ICRF193 treated HCT116 cells, the phosphorylations
of ATM and Chk2 were not signiﬁcant, while treatment with etoposide
resulted in 37.74 ± 1.87 and 14.12 ± 0.91 fold increase in the
Fig. 4.Cell cycle arrest analysis inHCT116 cell line and activation of decatenation checkpoint pathway inHCT116 and HEK293T cell lines. (A) G2 phase synchronizedHCT116 cells (6 h post
thymidine release) were treated with vehicle or ICRF193 at the IC50 concentration and were ﬁxed at the indicated time points. Percentage of G2/M population was calculated by ﬂow
cytometry analysis. (B) Percentage of G2/Mpopulation in synchronizedHCT116 cells treatedwith vehicle or ICRF193 at 10 times above the IC50 concentration for the indicated time points.
(C) Percentage of G2/Mpopulation in asynchronously growingHCT116 cells treatedwith vehicle or ICRF193 at the IC50 concentration for the indicated timepoints. (D) Percentage of G2/M
population in asynchronously growing HCT116 cells treated with vehicle or ICRF193 at 10 times above the IC50 concentration for the indicated time points. Each error bar represents
mean ± SDM for the three independent experiments. *P b 0.05, t-test (ICRF193 versus vehicle). (E) Cyclin A2 and cyclin B1 levels in HCT116 and HEK293T cells. G2 phase synchronized
cells (6 h post-thymidine release) were treated with vehicle or ICRF193 or etoposide at the IC50 concentrations and harvested at 6, 7, 8, 9, 10, 11 and 12 h post-thymidine release. Immu-
noblotting was performed for cyclin A2, cyclin B1 and β-actin proteins. (F) ATM and Chk-2 phosphorylations in G2 phase synchronized HCT116 and HEK293T cell lines. G2 phase
cells were treated with vehicle or ICRF193 or etoposide at the IC50 concentrations for 2 h and immunoblotting was performed for p-ATM, p-Chk2 andβ-actin proteins. V= vehicle,
I = ICRF193, E = etoposide.
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versus etoposide) (Fig. 4F and Supplementary Fig. 7A). In HEK293T
cells, ICRF193 treatment induced 13.92± 1.11 and 11.77± 0.55 fold in-
crease in the phosphorylations of ATMand Chk2, respectively, (P b 0.05,
vehicle versus ICRF193) and etoposide treatment induced 23.18± 0.85
and 7.99 ± 0.84 fold increase in the phosphorylations of ATM andTable. 1
Percentage of G2/M population in synchronized HCT116 cells treated with vehicle or ICRF193 at th
percentage G2/M population ± SD, for the three independent experiments.
Time (post-thymidine release)
Treated at the IC50 concentration G1/S Synchronized cells (0 h)
6 h
8 h
10 h
12 h
14 h
Treated at 10 times above the IC50 concentration G1/S Synchronized cells (0 h)
6 h
8 h
10 h
12 h
14 hChk2, respectively, (P b 0.05, vehicle versus etoposide) (Fig. 4F and
Supplementary Fig. 7B). These results suggest that in HCT116 cells
upon ICRF193 treatment, decatenation checkpoint pathway is not
activated while upon etoposide treatment, DNA damage pathway is
activated and as a consequence ATM and Chk2 are phosphorylated.
Whereas in HEK293T cells upon ICRF193 treatment, decatenatione IC50 concentration or at 10 times above the IC50 concentration. Values are shown as mean
Vehicle treated cells
(mean % G2/M population ± SD)
ICRF193 treated cells
(mean % G2/M population ± SD)
3.45 ± 0.25 3.45 ± 0.25
59.66 ± 0.72 66.26 ± 1.92
61.66 ± 3.58 66.4 ± 4.36
50 ± 4.7 71.2 ± 2.43
28.46 ± 0.4 75.63 ± 1.23
22.93 ± 0.82 78.9 ± 0.57
5.6 ± 0.5 5.6 ± 0.5
68.7 ± 3.23 67.9 ± 2.28
64.2 ± 5.51 70.3 ± 5.66
53.43 ± 5.65 76.46 ± 4.23
31.26 ± 2.18 80.16 ± 1.94
25.2 ± 1.24 80.83 ± 1.93
Table. 2
Percentage of G2/M population in asynchronously growing HCT116 cells treated with vehicle or ICRF193 at the IC50 concentration or at 10 times above the IC50 concentration for the
indicated time points. Values are shown as mean percentage G2/M population ± SD, for the three independent experiments.
Treatment time Vehicle treated cells (mean % G2/M population ± SD) ICRF193 treated cells (mean % G2/M population ± SD)
Treated at the IC50 concentration 12 h 16.76 ± 0.40 58.66 ± 3.00
24 h 8.13 ± 0.61 71.03 ± 6.10
36 h 8.33 ± 0.66 78.16 ± 3.25
48 h 7.36 ± 0.80 85.66 ± 3.00
Treated at 10 times above the IC50 concentration 12 h 18.1 ± 0.96 85.86 ± 0.76
24 h 12.83 ± 0.45 87.86 ± 0.37
36 h 11.9 ± 1.01 91.93 ± 1.24
48 h 10.53 ± 1.32 93.1 ± 0.26
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damage checkpoint pathway is activated and as a consequence ATM
and Chk2 are phosphorylated in both the conditions.
3.5. ICRF193 and etoposide both inhibit DNA topoisomerase relaxation
activity in HCT116 and HEK293T cell lines
To understand whether ICRF193 and etoposide treatments inhibit
topoisomerase II enzyme in HCT116 and HEK293T cell lines, in vitro
DNA relaxation assays were performed using nuclear extracts from
ICRF193 and etoposide treated HCT116 and HEK293T cell lines. G2
phase synchronized HCT116 and HEK293T cell lines were treated with
vehicle or 4 μM ICRF193 or 4 μM etoposide for 2 h and nuclear extracts
were prepared as described in the Materials and methods section. Nu-
clear extracts from vehicle treated cells efﬁciently relaxed supercoiled
DNA while nuclear extracts from ICRF193 and etoposide treated cells
were partially inefﬁcient in relaxing supercoiled DNA (Fig. 5A and B),
suggesting that both ICRF193 and etoposide inhibit topo II enzyme
activity in these cells. Residual relaxation activities are due to the
other forms of topoisomerases present in the nuclear extracts.
3.6. ICRF193 treatment generates under-condensed and entangled mass of
chromosomes in HCT116 cells
To examine chromosomal morphology Giemsa staining was per-
formed. G2 phase synchronized HCT116 cells were treated with vehicle
or 4 μM ICRF193 for 2 h. Cells were lysed by hypotonic treatment, nuclei
were ﬁxed in acetic acid methanol mixture and Giemsa staining was
performed. In vehicle treated cells perfectly condensed and decatenated
chromosomes were observed whereas in ICRF193 treated cells under-
condensed and entangled masses of chromosomes were observed
(Fig. 5C), suggesting that ICRF193 inhibits topo IIαmediated chromo-
somal decatenation in the decatenation checkpoint defective HCT116
cell line.
3.7. ICRF193 treatment induces mitotic catastrophe and apoptotic cell death
in HCT116 cells
Cells undergoing mitotic catastrophe can be distinguish by their
large fragmented multinuclei [22]. To assess mitotic catastrophe induc-
tion in response to ICRF193 treatment, HCT116 cells were treated with
vehicle or 1 or 2 or 3 μM ICRF193 for 48 h and 72 h and nuclei were
stained with DAPI for microscopic observation. In cells treated for 48 h
with vehicle, 1, 2 and 3 μM ICRF193; 1.06 ± 0.48%, 24.6 ± 7.34%,Table. 3
Extents of G2 decatenation/damage checkpoint function in the six cell lines. Values are shown
HCT116 HT-29
G2 decatenation checkpoint function (%) 4.52 ± 3.38 10.77 ± 4.45
G2 DNA damage checkpoint function (%) 70.18 ± 16.14 67.6 ± 8.2539.72±0.55% and51.16±5.02%multinucleiwere observed, respectively
(Fig. 6A andB, Supplementary Fig. 8). In cells treated for 72 hwith vehicle,
1, 2 and 3 μM ICRF193; 0.64 ± 0.27, 43.56 ± 0.96%, 54.98 ± 2.66%
and 69.04 ± 3.46% multinuclei were observed, respectively. These
observations suggest that ICRF193 induces mitotic catastrophe in the
decatenation checkpoint defective HCT116 cells. Since mitotic catastro-
phe shares some characteristics of apoptotic cell death therefore we ana-
lyzed the induction of early and late apoptosis in ICRF193 and etoposide
treatedHCT116 cells. Asynchronously growingHCT116 cellswere treated
with vehicle or ICRF193 or etoposide at IC50 concentrations or at 10 times
above the IC50 concentrations for 48 and 72 h and were stained with
annexin V-propidium iodide solution for ﬂow cytometry analysis. The
aim of using ICRF193 or etoposide concentrations at 10 times above the
IC50 concentrations was to study more accurate comparison of effects of
ICRF193 and etoposide on the cell death. Both ICRF193 and etoposide in-
duced apoptosis after 48 and 72 h of treatments and the apoptosis was
comparatively higher in ICRF193 treated conditions than etoposide treat-
ed conditions (Fig. 6C and D, Supplementary Fig. 9A and B). After 48 h
treatment with vehicle, ICRF193 and etoposide at IC50 concentrations,
5.2 ± 1.53%, 39.83 ± 4.80% and 24.06 ± 5.43% cells were apoptotic, re-
spectively, which after 72 h increased to 7.16 ± 2.10%, 45.83 ± 4.1%
and 41.7 ± 6.26%, respectively. After 48 h treatment with vehicle,
ICRF193 and etoposide at 10 times above the IC50 concentrations,
8.56 ± 5.4%, 47.9 ± 5.99% and 47.06 ± 2.05% were apoptotic, respec-
tively, which after 72 h increased to 0.76 ± 0.46%, 74.86 ± 4.70% and
56.2 ± 3.95%, respectively. Apoptosis induction was also analyzed in
synchronously growing HCT116 cells. G2 phase synchronized cells
were treated with vehicle or ICRF193 or etoposide at IC50 concentra-
tions or at 4 μM concentrations for 20, 24, 28 and 32 h (Fig. 6E and F,
Supplementary Fig. 9C and D, Supplementary Fig. 10). Percentages of
apoptotic cells were very high in 4 μM ICRF193 and 4 μM etoposide
treated conditions. This elevated apoptosis could be due to the effect
of cell synchronization, making the cells more vulnerable for ICRF193
and etoposide treatments.4. Discussion
Our study demonstrates that the ICRF193 sensitive colon cancer cell
lines have defects in the decatenation checkpoint function and such
checkpoint defective cells upon inhibition of DNA decatenation are not
arrested in G2 phase but enter into M phase and are accumulated at
early metaphase stage. Our study also demonstrates that extent of the
G2 decatenation checkpoint function varies among the ICRF193 sensi-
tive colon cancer cell lines. Our ﬁndings are in support with a previousas mean percentage checkpoint function ± SD, for the three independent experiments.
Caco2 Colo205 SW480 HEK293T
13.41 ± 5.61 29.02 ± 5.37 79.35 ± 2.55 81.4 ± 3.5
48.96 ± 10.62 59.67 ± 17.35 63.74 ± 8.83 66.86 ± 4.27
Fig. 5. DNA topoisomerase relaxation assays and Giemsa staining of chromosomes. (A) DNA relaxation assay for nuclear extracts from HCT116 cells. G2 phase cells were treated with
vehicle or 4 μM ICRF193 or 4 μM etoposide for 2 h and nuclear extracts were prepared. (B) DNA relaxation assay for nuclear extracts from HEK293T cells. V = vehicle, I = ICRF193,
E = etoposide. (C) Giemsa stained metaphase chromosomes from vehicle and 4 μM ICRF193 treated HCT116 cells. The G2 phase cells were treated with vehicle or ICRF193 for 2 h and
Giemsa staining was performed.
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U2OS cell lines, the inhibition of DNAdecatenation duringmitosis arrest
cell cycle inmetaphase. Spindle assembly checkpoint also arrests cells in
metaphase but the metaphase arrest in response to inhibition of chro-
mosomal decatenation does not involve recruitment of Mad2 and
Bub1 at kinetochores [27,28]. Damelin et al. [29], have shown that
decatenation checkpoint is highly inefﬁcient in mice embryonic stem
cells, inmice neural progenitor cells and in human CD34+ hematopoietic
progenitor cells. They also showed that the checkpoint efﬁciency is in-
creasedwhen embryonic stem cells are induced to differentiate, suggest-
ing that the checkpoint deﬁciency is a feature of the undifferentiated
state. According to Franchitto et al. [30], Werner syndrome cells have de-
fects in G2 decatenation checkpoint function and WRN, a RecQ helicase,
plays role in the activation of the checkpoint pathway. Defects in
the G2 decatenation checkpoint have been shown in lung cancer
[3], bladder cancer [4], Werner syndrome cells [30] and recently in
melanoma [5]. It has also been shown that cancer stem cells have de-
fects in the G2 decatenation checkpoint [7,29,31]. Recently Brooks
et al. [32], have shown that melanoma cells defective in decatenation
checkpoint function require phosphatidylinositol 3-kinase (PI3K) for
their survival.
ATM auto-phosphorylation at serine-1981 in response to ICRF193
treatment contributes to the activation of G2 decatenation checkpoint
[12]. We found that in HCT116 cells ATM and Chk2 kinases are not
phosphorylated in response to ICRF193 treatment. Contrary to this, in
HEK293T cells both the kinases are phosphorylated in response
to ICRF193 treatment. Lossaint et al. [33], have also previously shown
that 12 h treatment of ICRF193 in HCT116 cell line does not induce ATM
and Chk2 phopsphorylations, whereas 12 h treatment of bleomycin (a
DNA damaging agent) efﬁciently induces ATM and Chk2 phops-
phorylations in this cell line. We also found that in HCT116 cells, upon
ICRF193 treatment, chromosomes become under-condensed, catenated
and remain as entangled mass. Checkpoint deﬁcient cells, particularly
DNA structure checkpoint or spindle assembly checkpoint deﬁcient cells
have been shown to undergo mitotic catastrophe [34]. Failure to arrest
the cell cycle before or at mitosis triggers an attempt of aberrant chromo-
some segregation, which may result in to chromosomal breakage oraneuploidy and may participate in oncogenesis. Thus in order to prevent
oncogenesis and/or aneuploidy such checkpoint deﬁcient cells induce
mitotic catastrophe leading to cell death [22,35]. Therefore we suspected
that the decatenation checkpoint defective HCT116 cells, which are
accumulated in early metaphase stage with entangled chromosomes
in response to ICRF193 treatment, may undergo mitotic catastrophe.
We found that treatmentwith ICRF193 for 48 and 72 h results in the for-
mation of fragmented and large nuclei (multi-nuclei), which are indic-
ative of mitotic catastrophe [22]. Mitotic catastrophe shares some
characteristics of apoptosis. Therefore we studied induction of apopto-
sis in the decatenation checkpoint defective HCT116 cells and found
that treatment with ICRF193 for 48 and 72 h results in signiﬁcant
increase in the early and late apoptotic cells. Nakagawa et al. [3], have
previously shown that decatenation checkpoint defective cells show
hypersensitivity for ICRF193 treatment. Our ﬁndings allow us to pro-
pose that mitotic catastrophe could be one reason behind the elevat-
ed sensitivity and rapid death of decatenation checkpoint defective
cells in response to ICRF193 treatment. The induction of mitotic ca-
tastrophe in checkpoint defective cells is considered as an important
therapeutic endpoint and can be a desirable goal in cancer treatment
[36,37].5. Conclusions
Majority of colon cancer cell lines have defects in the G2 decatenation
checkpoint function at different extents and such decatenation check-
point defective cell lines are comparatively more sensitive for ICRF193
(a catalytic inhibitor of topo IIα) than checkpoint proﬁcient cells.
ICRF193 selectively kills decatenation checkpoint defective colon cancer
cells by inducing mitotic catastrophe and apoptosis and thus catalytic in-
hibitors of topo IIα are promising therapeutic agents for the treatment of
colon cancers with defective decatenation checkpoint. Our study also
suggests that decatenation checkpoint defects may be a common feature
in colorectal cancers and such defectsmay play important roles in the de-
velopment and progression of colorectal cancers by gradually increasing
predisposition of genetic instabilities.
Fig. 6.Mitotic catastrophe and apoptotic cell death in ICRF193 treated HCT116 cells. (A) and (B) Assessment of mitotic catastrophe in HCT116 cells treated with vehicle or 1 or 2 or 3 μM
ICRF193 for 48 and 72 h. Percentage of multinucleated cells was counted in each condition and plotted with respect to ICRF193 doses. (C) and (D) detection of apoptosis induction in
HCT116 cells treated with vehicle or ICRF193 or etoposide at the IC50 or at 10 times above the IC50 concentrations for 48 and 72 h. Cells were stained with FITC-annexin V and propidium
iodide solutions and ﬂow cytometry was performed. (E) Detection of apoptosis induction in G2 phase synchronized HCT116 cells treated with vehicle, ICRF193 and etoposide at the IC50
concentrations for 20, 24, 28 and 32 h. (F) Detection of apoptosis induction in G2 phase synchronized HCT116 cells treated with vehicle, ICRF193 and etoposide at 4 μM concentrations for
20, 24, 28 and 32 h. Each error bar represents mean ± SDM for the three independent experiments. *P b 0.05, t-test (vehicle versus treated).
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